Monte Rosa Therapeutics Announced MRT-8102 Is Expected To Be Developed For Inflammatory Diseases Driven By Interleukin-1β And The NLRP3 Inflammasome. This Is The First Development Candidate To Be Declared From The Company's NEK7 Development Program
Monte Rosa Therapeutics 宣布，MRT-8102 有望开发用于白介素-1β 和 NLRP3 炎症体驱动的炎性疾病。这是该公司NEK7开发计划中宣布的第一个开发候选人